Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Current Assets (2020 - 2025)

Apellis Pharmaceuticals has reported Current Assets over the past 6 years, most recently at $1.0 billion for Q4 2025.

  • Quarterly results put Current Assets at $1.0 billion for Q4 2025, up 28.63% from a year ago — trailing twelve months through Dec 2025 was $1.0 billion (up 28.63% YoY), and the annual figure for FY2025 was $1.0 billion, up 28.63%.
  • Current Assets for Q4 2025 was $1.0 billion at Apellis Pharmaceuticals, up from $990.7 million in the prior quarter.
  • Over the last five years, Current Assets for APLS hit a ceiling of $1.1 billion in Q1 2022 and a floor of $475.4 million in Q3 2021.
  • Median Current Assets over the past 5 years was $817.7 million (2021), compared with a mean of $826.8 million.
  • Biggest five-year swings in Current Assets: tumbled 35.96% in 2021 and later skyrocketed 74.99% in 2022.
  • Apellis Pharmaceuticals' Current Assets stood at $824.0 million in 2021, then dropped by 12.68% to $719.5 million in 2022, then increased by 6.51% to $766.3 million in 2023, then increased by 2.95% to $789.0 million in 2024, then increased by 28.63% to $1.0 billion in 2025.
  • The last three reported values for Current Assets were $1.0 billion (Q4 2025), $990.7 million (Q3 2025), and $755.6 million (Q2 2025) per Business Quant data.